Nanoscale Delivery Systems in Treatment of Posterior Ocular Neovascularization: Strategies and Potential Applications

References

• WHO . Global Data On Visual Impairments 2010. (2012).
   Google Scholar
• Kompella U , AmriteA , RaviR , DurazoS. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Progr. Retinal Eye Res.36, 172–198 (2013).
   PubMed Web of Science ®Google Scholar
• Falavarjani KG , SaddaSR. Hot topics in pharmacotherapy for neovascular age-related macular degeneration. Curr. Pharm. Design.23(4), 535–541 (2017).
   PubMed Web of Science ®Google Scholar
• Falavarjani KG , NguyenQD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond).27(7), 787–794 (2013).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA . Ocular neovascularization. J. Mol. Med. (Berl.).91(3), 311–321 (2013).
   PubMed Web of Science ®Google Scholar
• Shen HH , ChanEC , LeeJHet al. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery. Nanomedicine10(13), 2093–2107 (2015).
   PubMed Web of Science ®Google Scholar
• Renner M , StuteG , AlzureiqiMet al. Optic nerve degeneration after retinal ischemia/reperfusion in a rodent model. Front Cell Neurosci.11, 254 (2017).
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA , NegraoS , IidaTet al. Retinal angiomatous proliferation in age-related macular degeneration. Retina21(5), 416–434 (2001).
   PubMed Web of Science ®Google Scholar
• Neri P , LettieriM , FortunaC , ManoniM , GiovanniniA. Inflammatory choroidal neovascularization. Middle East Afr. J. Ophthalmol.16(4), 245–251 (2009).
   PubMedGoogle Scholar
• Ambati J , FowlerBJ. Mechanisms of age-related macular degeneration. Neuron75(1), 26–39 (2012).
   PubMed Web of Science ®Google Scholar
• Tsai ASH , CheungN , GanATLet al. Retinal angiomatous proliferation. Surv. Ophthalmol.62(4), 462–492 (2017).
   PubMed Web of Science ®Google Scholar
• Andrei O , Denissa-GretaO , AndreeaNet al. Retinal angiomatous proliferation case report. Rom. J. Ophthalmol.59(3), 167–171 (2015).
   PubMedGoogle Scholar
• Halasz K , KellyS , SutariyaV. Hypoxia inducible factor-1 (HIF-1) as a target for ocular drug delivery. J. Biomol. Res. Ther.06(01), e154 (2017).
   Google Scholar
• Qazi Y , MaddulaS , AmbatiBK. Mediators of ocular angiogenesis. J. Genet.495–515 (2009).
   PubMed Web of Science ®Google Scholar
• Nakao S , HataY. Chapter 13 - an overview of diabetes and ocular health. In: Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. BagchiD, SreejayanN ( Eds). Elsevier, London, UK, 159–176 (2012).
   Google Scholar
• Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management: Diabetic Retinopathy Vitrectomy Study (DRVS) Report #1. Ophthalmology92(4), 492–502 (1985).
   PubMed Web of Science ®Google Scholar
• Dave VP , PathengayA , SchwartzSG , FlynnHWJr. Endophthalmitis following pars plana vitrectomy: a literature review of incidence, causative organisms, and treatment outcomes. Clin. Ophthalmol.8, 2183–2188 (2014).
   PubMedGoogle Scholar
• Tang J , ShakinEP. Choroidal neovascularization after vitrectomy surgery for macular disease. Investig. Ophthalmol. Vis. Sci.43(13), U594–U594 (2002).
   Google Scholar
• Emoto H , EmotoY , LimJI , SadunAA , SebagJ. Regression of choroidal neovascularization after vitrectomy for postinjection endophthalmitis. Retinal Cases Brief Rep.4(4), 312–316 (2010).
   PubMedGoogle Scholar
• Al-Shabrawey M , ElsherbinyM , NussbaumJ , OthmanA , MegyerdiS , TawfikA. Targeting neovascularization in ischemic retinopathy: recent advances. Expert Rev. Ophthalmol.8(3), 267–286 (2013).
   PubMedGoogle Scholar
• Ferris FL 3rd . How effective are treatments for diabetic retinopathy?JAMA269(10), 1290 (1993).
   PubMed Web of Science ®Google Scholar
• Neely KA , GardnerTW. Ocular neovascularization: clarifying complex interactions. Am. J. Pathol.153(3), 665–670 (1998).
   PubMed Web of Science ®Google Scholar
• Hawkins B , FineS , DonaldJ , GassM. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch. Ophthalmol.104(5), 694–701 (1986).
   PubMedGoogle Scholar
• Ferris FL 3rd . A new treatment for ocular neovascularization. N. Engl. J. Med.351(27), 2863–2865 (2004).
   PubMed Web of Science ®Google Scholar
• Hawkins B . Argon-laser photocoagulation for neovascular maculopathy 5-year results from randomized clinical-trials. Arch. Ophthalmol.109(8), 1109–1114 (1991).
   PubMedGoogle Scholar
• Dougherty TJ , MarcusSL. Photodynamic therapy. Eur. J. Cancer28(10), 1734–1742 (1992).
   Google Scholar
• Bressler NM . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin – one-year results of 2 randomized clinical trials – TAP report 1. Arch. Ophthalmol.117(10), 1329–1345 (1999).
   PubMedGoogle Scholar
• Group VIPTS . Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol.131(5), 541–560 (2001).
   PubMed Web of Science ®Google Scholar
• Azab M , BoyerDS , BresslerNMet al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch. Ophthalmol.123(4), 448–457 (2005).
   PubMedGoogle Scholar
• Newman DK . Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond.)30(2), 202–210 (2016).
   PubMed Web of Science ®Google Scholar
• Adamis AP , MillerJW , BernalMTet al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol.118(4), 445–450 (1994).
   PubMed Web of Science ®Google Scholar
• Aiello LP , AveryRL , ArriggPGet al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med.331(22), 1480–1487 (1994).
   PubMed Web of Science ®Google Scholar
• Gragoudas ES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR; VISIONCT Group. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med.351(27), 2805–2816 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ , BrownD , HeierJet al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355(14), 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Bakall B , FolkJC , BoldtHCet al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am. J. Ophthalmol.156(1), 15–22 e11 (2013).
   PubMed Web of Science ®Google Scholar
• Rich RM , RosenfeldPJ , PuliafitoCAet al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina26(5), 495–511 (2006).
   PubMed Web of Science ®Google Scholar
• Kim K , ParkSW , KimJHet al. Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. Genome Res.27(3), 419–426 (2017).
   PubMed Web of Science ®Google Scholar
• Mark R , BarakatPUD. New developments for the treatment of exudative and nonexudative AMD. Ret. Phys.12, 32–36 (2015).
   Google Scholar
• Patra JK , DasG , FracetoLFet al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol.16(1), 71 (2018).
   PubMed Web of Science ®Google Scholar
• Cholkar K , PatelA , VadlapudiAD , MitraAK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat. Nanomed.2(2), 82–95 (2012).
   PubMedGoogle Scholar
• Iyer S , RadwanAE , Hafezi-MoghadamA , MalyalaP , AmijiM. Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration. J. Control. Release.296, 140–149 (2019).
   PubMed Web of Science ®Google Scholar
• Araujo J , NikolicS , EgeaMA , SoutoEB , GarciaML. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surfaces B Biointerfaces88(1), 150–157 (2011).
   PubMed Web of Science ®Google Scholar
• Apaolaza PS , DelPozo-Rodriguez A , SolinisMAet al. Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles. Biomaterials90, 40–49 (2016).
   PubMed Web of Science ®Google Scholar
• Bhatt P , LalaniR , VhoraIet al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: enhanced loading efficiency and its pharmacokinetic evaluation. Int. J. Pharm.536(1), 95–107 (2018).
   PubMed Web of Science ®Google Scholar
• Battaglia L , SerpeL , FogliettaFet al. Application of lipid nanoparticles to ocular drug delivery. Expert Opin. Drug Deliv.13(12), 1743–1757 (2016).
   PubMed Web of Science ®Google Scholar
• Freitas LGA , IsaacDLC , LimaEMet al. Retinal changes in rabbit after intravitreal injection of sunitinib encapsulated into solid lipid nanoparticles and polymeric nanocapsules. Arq. Bras. Oftalmol.81(5), 408–413 (2018).
   PubMed Web of Science ®Google Scholar
• Mu H , WangY , ChuYet al. Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. Drug Deliv.25(1), 1372–1383 (2018).
   PubMed Web of Science ®Google Scholar
• Narvekar P , BhattP , FnuG , SutariyaV. Axitinib-loaded poly(lactic-co-glycolic acid) nanoparticles for age-related macular degeneration: formulation development and in vitro characterization. Assay Drug Dev. Technol.17(4), 167–177 (2019).
   PubMed Web of Science ®Google Scholar
• Patel J , AmrutiyaJ , BhattP , JaviaA , JainM , MisraA. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J. Microencapsul.35(2), 204–217 (2018).
   PubMed Web of Science ®Google Scholar
• Varshochian R , Riazi-EsfahaniM , Jeddi-TehraniMet al. Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J. Biomed. Mater. Res. Part A103(10), 3148–3156 (2015).
   PubMed Web of Science ®Google Scholar
• Kelly SJ , HiraniA , ShahidadpuryVet al. Aflibercept nanoformulation inhibits VEGF expression in ocular in vitro model: a preliminary report. Biomedicines6(3), 92 (2018).
   PubMed Web of Science ®Google Scholar
• Pan CK , DurairajC , KompellaUBet al. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J. Ocul. Pharmacol. Ther.27(3), 219–224 (2011).
   PubMed Web of Science ®Google Scholar
• Thackaberry EA , FarmanC , ZhongFet al. Evaluation of the toxicity of intravitreally injected PLGA microspheres and rods in monkeys and rabbits: effects of depot size on inflammatory response. Investig. Ophthalmol. Vis. Sci.58(10), 4274–4285 (2017).
   PubMed Web of Science ®Google Scholar
• Gross N , RanjbarM , EversCet al. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol. Vis.19, 54–61 (2013).
   PubMed Web of Science ®Google Scholar
• Liu HA , LiuYL , MaZZ , WangJC , ZhangQ. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model. Investig. Ophthalmol. Vis. Sci.52(7), 4789–4794 (2011).
   PubMed Web of Science ®Google Scholar
• Iwase T , FuJ , YoshidaTet al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J. Control. Release.172(3), 625–633 (2013).
   PubMed Web of Science ®Google Scholar
• Wang Z , ChengR , LeeKet al. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler. Thromb. Vasc. Biol.35(4), 855–864 (2015).
   PubMed Web of Science ®Google Scholar
• Kim H , ChoiJS , KimKS , YangJA , JooCK , HahnSK. Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization. Acta Biomater.8(11), 3932–3940 (2012).
   PubMed Web of Science ®Google Scholar
• Marano RJ , TothI , WimmerN , BrankovM , RakoczyPE. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther.12(21), 1544–1550 (2005).
   PubMed Web of Science ®Google Scholar
• Tyagi P , BarrosM , StansburyJW , KompellaUB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol. Pharm.10(8), 2858–2867 (2013).
   PubMed Web of Science ®Google Scholar
• Yavuz B , PehlivanSB , ÜnlüNet al. Dendrimeric systems and their applications in ocular drug delivery. Sci. World J.2013, 13 (2013).
   Google Scholar
• Bhatt P , NarvekarP , LalaniR , ChouguleMB , PathakY , SutariyaV. An in vitro assessment of thermo-reversible gel formulation containing sunitinib nanoparticles for neovascular age-related macular degeneration. AAPS PharmSciTech.20(7), 281 (2019).
   PubMed Web of Science ®Google Scholar
• Hirani A , GroverA , LeeYW , PathakY , SutariyaV. Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration. Pharm. Dev. Technol.21(1), 61–67 (2016).
   PubMed Web of Science ®Google Scholar
• Yuan X , MarcanoDC , ShinCSet al. Ocular drug delivery nanowafer with enhanced therapeutic efficacy. ACS Nano9(2), 1749–1758 (2015).
   PubMed Web of Science ®Google Scholar
• Lee SS , HughesP , RossAD , RobinsonMR. Biodegradable implants for sustained drug release in the eye. Pharm. Res.27(10), 2043–2053 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao M , Rodriguez-VillagraE , KowalczukLet al. Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. J. Control. Release266, 187–197 (2017).
   PubMed Web of Science ®Google Scholar
• Bourges JL , BloquelC , ThomasAet al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Deliv. Rev.58(11), 1182–1202 (2006).
   PubMed Web of Science ®Google Scholar